Kiely C J, Subramaniam K, Platten J, Pavli P
Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia.
Intern Med J. 2016 May;46(5):616-9. doi: 10.1111/imj.13057.
Biological therapy, particularly the anti-tumour necrosis factor (TNF) antibodies, infliximab and adalimumab, are used for the maintenance of remission for patients with inflammatory bowel diseases (IBD). We present 21 pregnancies in IBD patients exposed to anti-TNF agents between 2007 and 2014. Our study demonstrates that anti-TNF therapy is safe and effective in pregnancy. Rates of foetal complications are similar to IBD cohorts from the pre anti-TNF era.
生物疗法，尤其是抗肿瘤坏死因子（TNF）抗体、英夫利昔单抗和阿达木单抗，用于维持炎症性肠病（IBD）患者的缓解状态。我们报告了2007年至2014年间21例暴露于抗TNF药物的IBD患者的妊娠情况。我们的研究表明，抗TNF治疗在妊娠期是安全有效的。胎儿并发症发生率与抗TNF时代之前的IBD队列相似。
